Clinical trial Recruiting at 1 site Observational Ages 18 and up

Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

Official title: Establishment and Validation of an Early Warning Model for Acute Kidney Injury During the Perioperative Period of Cardiovascular Diseases.

Run by China National Center for Cardiovascular Diseases · NCT07749417 · Data updated 2026-11-12

This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment436 (estimated)
SponsorChina National Center for Cardiovascular Diseases
Government
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedJuly 17, 2026
Main results expectedJuly 2029
Study endsJuly 2029
Registry record updatedAugust 6, 2026
Trial IDNCT07749417 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) scheduled for elective cardiovascular surgery or contrast-enhanced imaging (CTA/PCI) and those with AKI risk who may develop CSA-AKI or CA-AKI.

Probably not a fit

Patients with advanced kidney disease requiring renal replacement therapy or those with AKI who do not recover prior to the exposure are less likely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects continuous perioperative GFR data using a fluorescence-based tracer to see if GFR trajectories can forecast CSA-AKI and CA-AKI before standard criteria are met. Participants are adults undergoing elective cardiovascular surgery, CTA, or PCI who receive the fluorescent tracer. Researchers compare GFR trajectories with subsequent AKI development and severity to identify early patterns. Data will include perioperative and peri-contrast hemodynamics and other clinical characteristics to contextualize the findings. The goal is to determine whether real-time kidney function monitoring can enable earlier recognition of AKI risk.

Why it matters

Potential benefit: If successful, this approach could allow earlier detection of AKI risk and timely interventions for patients undergoing cardiovascular procedures or contrast exposure.

How similar studies have gone: Prior studies in similar imaging-based kidney monitoring approaches have shown promise, but this specific perioperative fluorescence GFR trajectory method remains exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years old;
2. Specific inclusion criteria for the cohort:

   * GFR trajectory characterization after cardiovascular surgery or Iodine contrast agent exposure: Patients scheduled for elective cardiovascular surgery or interventional cardiovascular surgery or CTA; ② GFR trajectory characterization of AKI: Patients with confirmed CSA-AKI or contrast-associated acute kidney injury (CA-AKI).

Exclusion Criteria:

1. Received renal replacement therapy before surgery or before contrast imaging, including kidney transplantation and regular dialysis;
2. Serum creatinine \> 353 μmol/L before surgery or before contrast imaging;
3. Patients with AKI who did not recover before surgery or before contrast imaging;
4. Patients with malignant tumors.

Where it's running

  • Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.